Clinical Study | Office of Clinical Research

Artios Novartis Omb157g23101

Posted Date: Feb 15, 2021

Investigator: Aram Zabeti
Specialties: Multiple Sclerosis, Neurology
Type of Study: Drug

A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy

Criteria:

Participant Must Be Between 18-60 That Has Been Diagnosed With Relapsing Forms Of Ms (Rms) And Secondary Progressive Ms (Spms). Must Have Ms Treatment History With A Max Of 3 Dmts.

Keywords:

Relapsing Multiple Sclerosis, Neurology, Secondary Progressive Multiple Sclerosis

For More Information:

Tiffany Rupert
513-558-0269
tiffany.rupert@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List